Prolonged-release pharmaceutical forms

Immediate-release pharmaceutical forms release the active substance shortly after ingestion; they usually need to be taken several times a day. On the other hand, prolonged-release pharmaceutical forms ensure the release of the active substance over a longer period, allowing the medicine to be taken just once a day. This improves patient compliance and makes treatment more effective.

As the medicine is released gradually and over a longer period, the fluctuations in the plasma concentration of the active substance are less pronounced than with immediate-release forms. As a result, side effects associated with substantial fluctuations can potentially be avoided, which results in safer treatment.

Gliclazide prolonged-release tablets for lowering blood glucose levels

The active substance, gliclazide, is incorporated in a homogeneous matrix that allows for an even distribution of the active substance and excipients. The matrix contains a cellulose polymer that swells upon contact with body fluids in the gastrointestinal tract to form a gel layer. The active substance is released through this gel.

Gliclazide is an active substance from the sulfonylurea class used for oral treatment of type 2 diabetes mellitus. Krka produces prolonged-release tablets in various strengths. Higher-strenght tablets have a score line that allows the tablet to be precisely divided, thus tailoring the dose to the patient’s needs.